EMERYVILLE, California., September 24, 2020 / PRNewswire / – Dynavax Technologies Company (NASDAQ: DVAX), a biopharmaceutical company focused on the development and commercialization of novel vaccines, today announced the appointment of Peter R. Paradiso, Ph.D. to its board of directors. In addition, the Company also announced that Michel ostrach, Senior Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO), has announced his intention to retire in 2021.
“We are delighted to welcome Peter to our board of directors. Peter brings more than three decades of expertise in strategic planning and vaccine development. our FDA approved adult hepatitis B vaccine and CpG 1018, our advanced adjuvant vaccine, “commented Ryan spencer, Managing Director of Dynavax. “At the same time, Michael’s skills, breadth of experience and unwavering commitment to Dynavax have been essential to the success of our business. He has been an exceptional leader, esteemed colleague and tremendous mentor. Although his contributions will be missed. , we wish him a good retirement and his next adventures. “
“I am delighted to join the Dynavax Board of Directors at this exciting time of company growth,” commented Pierre Paradiso, Ph.D. “I am impressed with the organization’s commercial execution for HEPLISAV-B and the considerable progress made in making their advanced adjuvant, CpG 1018, available to collaborative partners in the pursuit of protection. of the world against infectious diseases. “
“I am grateful for the opportunity to serve Dynavax and to work alongside the dedicated people in my groups and across our organization over the past 14 years to further our company’s mission of providing new vaccines. It is particularly gratifying that these efforts have resulted in the approval and commercialization of our two-dose hepatitis b vaccine for adults, HEPLISAV-B, as well as clinical trials of several COVID-19 vaccine candidates testing our adjuvant CpG 1018. . ”Said Mr. Ostrach.
Dr Paradiso has worked in vaccine development for over 30 years. He is currently the sole owner of Paradiso Biologics Consulting, LLC. and is a member of the R&D and Manufacturing Investment Committee (RDMIC) of the Coalition for Epidemic Preparedness Innovations (CEPI), which was established to make investment decisions for R&D and vaccine manufacturing under of the COVAX pillar of the ACT-Accelerator. In addition, he is chairman of a Procurement Reference Group (PRG) to advise the United Nations Children’s Fund (UNICEF) and the GAVI Alliance – formerly the Global Alliance for Vaccines and Immunization (GAVI) on purchasing rotavirus vaccines. Dr. Paradiso retired in 2012 where he served as Vice President, New Business and Scientific Affairs for Pfizer Vaccines, a division of Pfizer, Inc. In this position, Dr. Paradiso was responsible for global scientific affairs and strategic planning within the vaccine research and development group and for the commercial oversight of products in development. Dr. Paradiso obtained a Doctor of Philosophy (Ph.D.) in biochemistry from University of Vermont College of Medicine and a BS in Chemistry from Saint-Laurent University.
As part of the transition planned for next year, Dynavax has retained Russell Reynolds Associates to help the company recruit its next CFO. Mr. Ostrach will continue in his role as the Company identifies a successor. If a new CFO is appointed before March 31, 2021, Mr. Ostrach has agreed to remain in an advisory capacity until the completion of the Company’s report on 2020 financial results and to remain available as an advisor to the Company. afterwards. The Company does not intend to fill the CBO position upon Mr. Ostrach’s retirement.
Dynavax is a commercial-stage biopharmaceutical company that develops and markets new vaccines. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States for the prevention of infections caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. Dynavax is also continuing the development of CpG 1018 as an advanced vaccine adjuvant through collaborations and research partnerships. Current collaborations focus on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information visit www.dynavax.com and follow the company on LinkedIn.
Nicole arndt, Senior Director, Investor Relations
Derek cole, President
Investor Relations Consulting Solutions
SOURCE Dynavax Technologies